Sequenom Shares Pushed Upward in November as Decode Collapsed | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Sequenom climbed 49 percent during the month of November as the firm tries to rebound from a clinical study scandal that led to the dismissal of senior executives at the firm two months ago.

Sequenom led the 34 stocks that comprise the GenomeWeb Daily News Index, while Decode Genetics' shares dropped 88 percent as the firm filed for Chapter 11 bankruptcy protection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.